Decreased susceptibility to cephalosporins among gonococci: Data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011

The Lancet Infectious Diseases

Volumn 13, Issue 9, 2013, Pages 762-768

  Ison, Catherine A ^a   Town, Katy ^a   Obi, Chinelo ^a   Chisholm, Stephanie ^a   Hughes, Gwenda ^a   Livermore, David M ^b   Lowndes, Catherine M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; CEFIXIME; CEFTRIAXONE; DOXYCYCLINE; PENA PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHLAMYDIASIS; CLINICAL PRACTICE; FEMALE; GONORRHEA; HETEROSEXUAL MALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOSAICISM; NEISSERIA GONORRHOEAE; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEFIXIME; CEFTRIAXONE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENGLAND; FEMALE; GENES, BACTERIAL; GONORRHEA; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA GONORRHOEAE; PORINS; PREVALENCE; RISK FACTORS; SEXUAL BEHAVIOR; WALES; YOUNG ADULT;

EID: 84882620294     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70143-9     Document Type: Article

References (30)

1. Global incidence and prevalence of selected curable sexually transmitted infections-2008 WHO, (accessed May 9, 2013). http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf.
2. Annual epidemiological report 2011: reporting on 2009 surveillance data and 2010 epidemic intelligence data European Centre for Disease Prevention and Control, (accessed May 9, 2013). http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=767.
3. Sexually transmitted infections annual data Health Protection Agency, (accessed May 9, 2013). http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/STIs/STIsAnnualDataTables/.
4. Lewis DA The gonococcus fights back: is this time a knock out?. Sex Transm Infect 2010, 86:415-421.
5. Guidelines for the management of sexually transmitted diseases WHO, (accessed March 13, 2013). http://www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf.
6. Antimicrobial resistance data: gonorrhoea-GRASP, the gonococcal resistance to antimicrobials surveillance programme Health Protection Agency, (accessed March 13, 2013). http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Gonorrhoea/AntimicrobialResistance/.
7. Bignell CJ BASHH guideline for gonorrhoea. Sex Transm Infect 2004, 80:330-331.
8. Ito M, Yasuda M, Yokoi S, et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 2004, 48:3185-3187.
9. Unemo M, Nicholas RA Emergence of multidrug resistant, extensively drug-resistant and untreatable gonorrhoea. Future Microbiol 2012, 7:1-22.
10. Ison CA, Hussey J, Sankar N, Evans J, Alexander S Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011, 16:19833.
11. Forsyth S, Penney P, Rooney G Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011, 22:296-297.
12. Martin JE, Lester A, Price EV, et al. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955-1969. J Infect Dis 1970, 122:459-461.
13. Ndowa F, Lusti-Narasimhan M, Unemo M The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect 2012, 88:317-318.
14. Hughes G, Nichols T, Ison CA Estimating the prevalence of gonococcal resistance to antimicrobials in England and Wales. Sex Transm Infect 2011, 87:526-531.
15. Chisholm SA, Alexander S, Desouza-Thomas L, et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011, 66:2509-2512.
16. Ochiai S, Ishiko H, Yasuda M, et al. Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol 2008, 46:1804-1810.
17. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3 European Committee on Antimicrobial Susceptibility Testing, Jan 5, (accessed March 13, 2013). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf.
18. Performance standards for antimicrobial susceptibility testing: fifteenth informational supplement, M100-S20 2010, CLSI, Clinical and Laboratory Standards Institute, Wayne.
19. Andrews JM BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 2009, 64:454-489. for the BSAC Working Party on Susceptibility Testing.
20. Lindberg R, Fredlund H, Nicholas R, Unemo M Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007, 51:2117-2122.
21. Choudhury B, Risley CL, Ghani AC, et al. Identification of individuals with gonorrhoea within sexual networks: a population-based study. Lancet 2006, 368:139-146.
22. Fenton KA, Imrie J Increasing rates of sexually transmitted diseases in homosexual men in Western Europe and the United States: why?. Infect Dis Clin North Am 2005, 19:311-331.
23. Dowell D, Kirkcaldy RD Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Postgrad Med J 2013, 89:142-147.
24. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M In vitro activity of the new fluoroketolide solithromycin (CEM-10) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains including high-level antimicrobial resistance: potential treatment option for gonorrhoea?. Antimicrob Agents Chemother 2012, 56:2739-2742.
25. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. J Antimicrob Chemother 2010, 65:2141-2148.
26. Handsfield HH, Dalu ZA, Martin DH, Douglas JM, McCarty JM, Schlossberg D Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994, 21:107-111. the Azithromycin Gonorrhea Study Group.
27. Bignell C, Fitzgerald M UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011, 22:541-547. Guideline Development Group, British Association for Sexual Health and HIV UKBritish Association for Sexual Health and HIV UK.
28. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae WHO, (accessed Nov 22, 2012). http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf.
29. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe European Centre for Disease Prevention and Control, (accessed March 13, 2013). http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf.
30. Gonoccocal Resistance to Antimicrobials Surveillance Programme (GRASP) action plan for England and Wales: informing the public health response Health Protection Agency, February, (accessed April 3, 2013). http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1317137983229.